Journey Medical Corporation (DERM)
USD 7.03
(2.18%)
USD 7.03
(2.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -9.7 Million USD | -7.42% |
| 2022 | -9.03 Million USD | 81.24% |
| 2021 | -48.17 Million USD | -1593.78% |
| 2020 | -2.84 Million USD | -666.53% |
| 2019 | 502 Thousand USD | -99.76% |
| 2018 | 208.81 Million USD | 1362.93% |
| 2017 | -16.53 Million USD | 60.44% |
| 2016 | -41.79 Million USD | 61.03% |
| 2015 | -107.24 Million USD | -100.75% |
| 2014 | -53.42 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -6.28 Million USD | 35.23% |
| 2024 Q2 | -1.1 Million USD | 82.43% |
| 2023 Q1 | 5.67 Million USD | 162.75% |
| 2023 Q2 | 1.86 Million USD | -67.1% |
| 2023 FY | -9.7 Million USD | -7.42% |
| 2023 Q4 | -9.7 Million USD | 60.56% |
| 2023 Q3 | -24.61 Million USD | -1419.29% |
| 2022 Q2 | -23.3 Million USD | 12.01% |
| 2022 Q1 | -26.48 Million USD | 45.03% |
| 2022 Q4 | -9.03 Million USD | 39.97% |
| 2022 Q3 | -15.05 Million USD | 35.38% |
| 2022 FY | -9.03 Million USD | 81.24% |
| 2021 Q1 | 8.24 Million USD | 389.94% |
| 2021 Q2 | -6.78 Million USD | -182.32% |
| 2021 Q3 | -6.59 Million USD | 2.81% |
| 2021 Q4 | -48.17 Million USD | -630.2% |
| 2021 FY | -48.17 Million USD | -1593.78% |
| 2020 Q4 | -2.84 Million USD | 0.0% |
| 2020 FY | -2.84 Million USD | -666.53% |
| 2020 Q1 | 4.8 Million USD | 0.0% |
| 2019 Q2 | 211.72 Million USD | 87.89% |
| 2019 FY | 502 Thousand USD | -99.76% |
| 2019 Q3 | 279.51 Million USD | 32.02% |
| 2019 Q1 | 112.68 Million USD | -46.04% |
| 2018 Q2 | 103.99 Million USD | 1292.5% |
| 2018 Q3 | 135.78 Million USD | 30.57% |
| 2018 Q4 | 208.81 Million USD | 53.78% |
| 2018 FY | 208.81 Million USD | 1362.93% |
| 2018 Q1 | -8.72 Million USD | 47.25% |
| 2017 Q3 | -114.69 Million USD | 17.98% |
| 2017 Q2 | -139.84 Million USD | 30.74% |
| 2017 Q1 | -201.91 Million USD | -383.14% |
| 2017 FY | -16.53 Million USD | 60.44% |
| 2017 Q4 | -16.53 Million USD | 85.58% |
| 2016 FY | -41.79 Million USD | 61.03% |
| 2016 Q4 | -41.79 Million USD | 24.91% |
| 2016 Q3 | -55.65 Million USD | 73.62% |
| 2016 Q2 | -210.98 Million USD | -128.41% |
| 2016 Q1 | -92.37 Million USD | 13.87% |
| 2015 Q3 | -118.32 Million USD | -284.57% |
| 2015 Q2 | -30.76 Million USD | 38.71% |
| 2015 Q4 | -107.24 Million USD | 9.37% |
| 2015 FY | -107.24 Million USD | -100.75% |
| 2015 Q1 | -50.2 Million USD | 6.02% |
| 2014 Q4 | -53.42 Million USD | 0.0% |
| 2014 FY | -53.42 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 110.306% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 112.954% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 102.23% |
| Cosmos Health Inc. | 8.59 Million USD | 213.017% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -18.208% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 102.117% |
| Cronos Group Inc. | -663.32 Million USD | 98.536% |
| Incannex Healthcare Limited | -5.48 Million USD | -77.01% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 33.372% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 107.965% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -234.628% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 37.901% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 37.901% |
| SCYNEXIS, Inc. | -19.35 Million USD | 49.824% |
| Safety Shot Inc | -2.28 Million USD | -325.018% |
| Theratechnologies Inc. | 24.87 Million USD | 139.037% |
| Alpha Teknova, Inc. | 1.97 Million USD | 591.844% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 5023.203% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 102.244% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -285.278% |
| Dynavax Technologies Corporation | 106.63 Million USD | 109.105% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 101.557% |
| Radius Health, Inc. | 359.28 Million USD | 102.702% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -2.962% |
| Alvotech | 1.06 Billion USD | 100.912% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 92.579% |
| SIGA Technologies, Inc. | -148.68 Million USD | 93.47% |
| Shineco, Inc. | 29.29 Million USD | 133.147% |
| Silver Spike Investment Corp. | -32.61 Million USD | 70.228% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -91.863% |
| Embecta Corp. | 1.31 Billion USD | 100.74% |
| Harrow Health, Inc. | 116.41 Million USD | 108.34% |
| Procaps Group, S.A. | 242.93 Million USD | 103.997% |
| Biofrontera Inc. | 4.05 Million USD | 339.374% |
| DURECT Corporation | -7.65 Million USD | -26.849% |
| PainReform Ltd. | -7.95 Million USD | -22.126% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 71.041% |
| OptiNose, Inc. | 58.06 Million USD | 116.721% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -87.214% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 164.671% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 9185.805% |
| ProPhase Labs, Inc. | 19.23 Million USD | 150.486% |
| Phibro Animal Health Corporation | 454.84 Million USD | 102.135% |
| Procaps Group S.A. | 242.93 Million USD | 103.997% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 363.975% |
| Viatris Inc. | 17.13 Billion USD | 100.057% |
| Rockwell Medical, Inc. | 4.45 Million USD | 317.886% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -99.077% |
| Tilray Brands, Inc. | 158.97 Million USD | 106.107% |
| PetIQ, Inc. | 351.93 Million USD | 102.759% |
| Talphera, Inc. | -5.72 Million USD | -69.708% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 105.476% |
| Alimera Sciences, Inc. | 55.3 Million USD | 117.554% |
| Assertio Holdings, Inc. | -32.52 Million USD | 70.153% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -552.17% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 330.235% |
| Hempacco Co., Inc. | 13.61 Million USD | 171.313% |
| Alvotech | 1.06 Billion USD | 100.912% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 89.961% |
| Kamada Ltd. | -46.43 Million USD | 79.09% |
| Currenc Group, Inc. | -16.57 Million USD | 41.417% |
| Indivior PLC | -33.95 Million USD | 71.404% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 3826.005% |
| Flora Growth Corp. | -713 Thousand USD | -1261.711% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -18.208% |
| Evolus, Inc. | 63.7 Million USD | 115.24% |
| HUTCHMED (China) Limited | -197.45 Million USD | 95.083% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 102.026% |
| Akanda Corp. | 3.9 Million USD | 348.635% |